Archive for April, 2013

Drug Patent Expirations for Apr 16 2013

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

FDA Orange Book archives from 2005 to present

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents





Drug Patent Expirations for April 16 2013

Tradename Applicant Generic Name Patent
Expiration
ACUTECT Cis Bio Intl Sa technetium tc-99m apcitide Apr 16, 2013
CAVERJECT IMPULSE Pharmacia And Upjohn alprostadil Apr 16, 2013
GENOTROPIN PRESERVATIVE FREE Pharmacia And Upjohn somatropin recombinant Apr 16, 2013
NICODERM CQ Sanofi Aventis Us nicotine Apr 16, 2013
OXYCONTIN Purdue Pharma Lp oxycodone hydrochloride Apr 16, 2013

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.



DrugPatentWatch
Infographics

Future drug patent expirations by month

How Many Drug Patents Will Expire in the Coming
Months?

More
infographics &raquo





DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Drug Patent Expirations for Apr 14 2013

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Journal of Commercial Biotechnology

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents





Drug Patent Expirations for April 14 2013

Tradename Applicant Generic Name Patent
Expiration
RAPLON Organon Usa Inc rapacuronium bromide Apr 14, 2013

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.



DrugPatentWatch
Infographics

Which pharma companies have the most drug patents

Which Companies Have the Most Active Drug
Patents?

More
infographics &raquo





DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Where are India’s Drug Patents?

As I continue to investigate global biotechnology for Scientific American and international patenting trends for DrugPatentWatch.com, I came across a curious finding. I was looking at the global spread of US drug patents — to obtain global patent protection for drugs companies must file for patents in each of the jurisdictions that they seek protection, within […]


Drug Patent Expirations for Apr 3 2013

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Who are the leading pharmaceutical patent challengers? A report on<br />
Paragraph IV challenges

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents





Drug Patent Expirations for April 3 2013

Tradename Applicant Generic Name Patent
Expiration
BROVANA Sunovion arformoterol tartrate Apr 3, 2013

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.



DrugPatentWatch
Infographics

Which pharmaceutical companies have the most drugs

Which Companies Have the Most Branded
Drugs?

More
infographics &raquo





DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Scientific American Worldview Issue 5 at #BIO2013

I continue to measure global biotechnology innovation in the fifth  edition of Scientific American Worldview. This special publication is the foundation I use for my talks on global biotechnology (see my recent talk on Building Biotechnology in India). I will be serving on a panel on April 24th at 2pm, and Fareed Zakaria will be moderating […]


Which pharmaceutical companies face the most patent expirations this year?

This infographic from DrugPatentWatch shows that Sanofi Aventis Us, Merck, Glaxosmithkline, Abbvie, Abraxis Bioscience, Genzyme, Abbott Endocrine,Boehringer Ingelheim, Merck And Co Inc, and Vyteris face the most patent expirations this year. Perhaps not surprisingly, GlaxoSmithKline and Sanofi Aventis are also among the firms with the most drug patents. For more infographics, see the DrugPatentWatch Pharmaceutical Innovation Infographics. Do you have a response to this infographic? […]


Book signings at #bio2013

Join Michael Salgaller and I as we will be signing our books at the BIO bookstore on Tuesday April 23rd. Michael will be signing Biotechnology Entrepreneurship From Science to Solutions from 12:30 to 2pm. I will be signing Building Biotechnology, Best Practices in Biotechnology Business Development, the Journal of Commercial Biotechnology, and also giving demos of […]


Drug Patent Expirations for Mar 26 2013

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

DrugPatentWatch -- sales, statistics, drug application<br />
information

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents





Drug Patent Expirations for March 26 2013

Tradename Applicant Generic Name Patent
Expiration
LOVAZA Smithkline Beecham omega-3-acid ethyl esters Mar 26, 2013
SILENOR Somaxon doxepin hydrochloride Mar 26, 2013

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.



DrugPatentWatch
Infographics

Which drug companies face the most patent expirations

Which Companies Face the Most Patent
Expirations?

More
infographics &raquo





DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


The Answers are in the Crowd? (Part 2) [live from #bio2013]

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. A common first reaction to crowdfunding for life sciences may be to dismiss it out of hand. Given the undeniable chill in early stage funding, it is worth giving the […]